Search Results
Your search for 27 matches 3348 pages
Showing 551 - 600New Risk Stratification System for Completely Resected Stage II or III Colorectal Cancer
As reported in The Lancet Oncology, Kleppe et al have developed a risk stratification system using the DoMore-v1-CRC marker and pathologic staging markers that may permit many patients with stage II or III colorectal cancer to avoid adjuvant chemotherapy. As stated by the investigators, “The...
Cabozantinib Prolongs Progression-Free Survival in Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
As reported in The Lancet Oncology by Marcia S. Brose, MD, Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III COSMIC-311 trial has shown that cabozantinib produced a numerically higher objective response rate and significantly prolonged progression-free survival vs...
Addition of Selumetinib to Adjuvant Radioactive Iodine in High-Risk Differentiated Thyroid Cancer
As reported in the Journal of Clinical Oncology by Ho et al, the phase III ASTRA trial showed no improvement in complete remission rate with the addition of selumetinib to adjuvant radioactive iodine (RAI) in patients with high-risk differentiated thyroid cancer. As stated by the investigators,...
Midtreatment Imaging De-escalates Therapy for Half of Study Patients With Oropharyngeal Cancer
Positron-emission tomography (PET) scans obtained before and midway through treatment may be used to de-escalate therapy for patients with oropharyngeal cancer, leading to fewer side effects, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 An interim...
Head and Neck Cancer 2021–2022 Almanac
Head and neck cancer is the seventh most common cancer in the world, with 1.1 million new diagnoses reported annually.1 In the United States, the incidence of oral and pharyngeal cancers is over 54,000 cases per year, resulting in over 11,000 yearly deaths.2 Although smoking and alcohol consumption ...
International Career Joins Cancer Research and Clinical Care of Patients With Lung Cancer
Pilar Garrido, MD, PhD, is Head of the Medical Oncology Department, University Hospital Ramón y Cajal, Madrid. She is also Co-Director of the Cancer Research Group at Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Her main areas of research and clinical interest are thoracic tumors,...
MRI-Guided Ultrasound Focal Therapy May Delay or Avoid Prostatectomy or Radiotherapy in Patients With Intermediate-Risk Prostate Cancer
MRI-guided focused ultrasound focal therapy produced “a high degree of success” and “a low rate of genitourinary adverse events” when used to treat select patients with intermediate-grade prostate cancer, Behfar Ehdaie, MD, MPH, and colleagues reported in The Lancet Oncology.1 Dr. Ehdaie is...
Dong Quai
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the herb dong...
Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma
On May 27, 2022, tisagenlecleucel, a CD19 chimeric antigen receptor (CAR) T-cell therapy, was granted accelerated approval for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.1 Supporting Efficacy Data Approval was based on the multicenter ELARA...
Adding CT to X-Ray for Follow-up of Completely Resected NSCLC
In a French phase III trial (IFCT-0302) reported in The Lancet Oncology, Westeel et al found that a strategy including computed tomography (CT) and x-ray vs x-ray alone did not improve overall survival when used in the follow-up of patients with completely resected non–small cell lung cancer...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, 2022, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare...
Lisocabtagene Maraleucel in Second-Line Treatment of Large B-Cell Lymphoma
On June 24, 2022, lisocabtagene maraleucel was approved for adults with large B-cell lymphoma (LBCL) who have (1) refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or (2) refractory disease to first-line chemoimmunotherapy or relapse...
Expert Point of View: Javier Cortés, MD, PhD
The invited discussant of the updated APHINITY data was Javier Cortés, MD, PhD, Head of the International Breast Cancer Center in Barcelona. “I think we clearly learned two things from the data. One is that estrogen receptor positivity does not matter in terms of benefit from the addition of...
APHINITY Trial in Patients With HER2-Positive Early Breast Cancer: Update at 8 Years
Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...
Stem Cell Boost as Salvage Therapy for Severe Hematologic Toxicity After CD19 CAR T-Cell Therapy
In a retrospective study reported in a research letter in Blood Advances, Rejeski et al found that a stem cell boost was successful in treating severe hematologic toxicity in patients who had received CD19 chimeric antigen receptor (CAR) T-cell therapy for refractory B-cell malignancies. Study...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
Atezolizumab Plus Vemurafenib/Cobimetinib for Patients With BRAF V600–Mutated Melanoma and CNS Metastases
In the phase II TRICOTEL study reported in The Lancet Oncology, Reinhard Dummer, MD, and colleagues found that the combination of atezolizumab plus vemurafenib and cobimetinib produced durable intracranial responses in patients with BRAF V600–mutated melanoma and central nervous system (CNS)...
Study Tests Strategy for Reducing Colorectal Cancer Risk Among Patients With Familial Adenomatous Polyposis
Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying the rare genetic condition called familial adenomatous polyposis, looking for potential ways to prevent colorectal cancer in the general population at an earlier, more...
INTRIGUE Trial: Second-Line Ripretinib vs Sunitinib in Advanced GIST
As reported in the Journal of Clinical Oncology by Bauer et al, the phase III INTRIGUE trial showed no significant progression-free survival benefit with second-line ripretinib vs sunitinib in imatinib-pretreated patients with gastrointestinal stromal tumor (GIST), including among patients with KIT ...
Does Daily Insulin Dose Affect Cancer Risk in Patients With Type 1 Diabetes?
In an analysis reported in JAMA Oncology, Zhong and Mao found that a higher daily insulin dose was associated with an increased risk of cancer diagnosis in patients with type 1 diabetes. Study Details The analysis used data from the Diabetes Control and Complications Trial (DCCT) and the...
His Grandmother’s Death Inspires a Career in Oncology for Manmeet S. Ahluwalia, MD, MBA
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Manmeet S. Ahluwalia, MD, MBA, Deputy Director, Chief Scientific Officer, and Chief of Solid Tumor Medical Oncology at Miami Cancer Institute, where his research focuses on the development of new therapies for...
Immunotherapy for Gastrointestinal Malignancies: Is It Ready for Prime Time?
In less than a decade, immunotherapy has reshaped the treatment landscape of cancer, but some histologies tend to be more responsive to this modality than others. During the Society of Surgical Oncology 2022 International Conference on Surgical Care, Yuman Fong, MD, of the City of Hope Medical...
Brentuximab Vedotin Plus AVD vs ABVD for the First-Line Treatment of Early-Stage Unfavorable-Risk Hodgkin Lymphoma
In a European phase II trial (BREACH) reported in the Journal of Clinical Oncology, Fornecker et al found that brentuximab vedotin (BV) plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) improved the rate of positron-emission tomography (PET)-negative status after two cycles of treatment vs...
ATLAS Trial: Risk-Adapted Triplet Maintenance Therapy May Benefit Some Patients With Multiple Myeloma
For newly diagnosed patients with multiple myeloma participating in the international phase III ATLAS trial, use of carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after induction and autologous stem cell transplantation (ASCT) significantly reduced the risk of disease...
Consolidation Radiotherapy vs Autologous Stem Cell Transplantation for Primary CNS Lymphoma
As reported in the Journal of Clinical Oncology by Houillier et al, 8-year follow-up in the French phase II PRECIS trial has shown a maintained event-free survival benefit with autologous stem cell transplantation (ASCT) vs whole-brain radiotherapy (WBRT) as consolidation in patients aged ≤ 60...
PALOMA-2: No Overall Survival Benefit Reported With Palbociclib/Letrozole in Advanced Breast Cancer
The final overall survival analysis of the phase III PALOMA-2 trial has shown no significant benefit for palbociclib given with letrozole, vs letrozole and placebo, as a first-line treatment in hormone receptor–positive, HER2-negative metastatic breast cancer.1 The results were reported at the 2022 ...
ASCO Statement on Supreme Court Decision in Dobbs v Jackson Women’s Health Organization
On June 27, 2022, ASCO released a statement on the recent ruling in Dobbs v Jackson Women’s Health Organization. “ASCO is committed to the delivery of medically appropriate, equitable, evidence-based cancer care. For patients of child-bearing age, a cancer diagnosis raises medical considerations...
Survey Finds More Than 80% of Patients With Cancer and Survivors Say Copay Assistance Programs Help Them Afford Their Prescription Drugs
A new Survivor Views survey from the American Cancer Society Cancer Action Network (ACS CAN) showed that a majority of respondents (83%) who had applied to a copay assistance program and were accepted said the assistance enables them to get the medication they otherwise couldn’t afford. However,...
Eprenetapopt/Azacitidine Maintenance After Allogeneic HSCT for TP53-Mutant AML and MDS
In a phase II trial reported in the Journal of Clinical Oncology, Mishra et al found that maintenance treatment with the first-in-class small-molecule p53 reactivator eprenetapopt plus azacitidine following allogeneic hematopoietic stem cell transplantation (HSCT) was associated with “encouraging”...
Addition of Trabectedin to Doxorubicin in the First-Line Treatment of Advanced Leiomyosarcoma
In the French phase III LMS-04 trial reported in The Lancet Oncology, Pautier et al found that the addition of trabectedin to doxorubicin significantly prolonged progression-free survival as first-line treatment for patients with unresectable or metastatic leiomyosarcoma. Study Details In the...
Addition of Atezolizumab to Neoadjuvant Pertuzumab/Trastuzumab and Docetaxel in HER2-Positive Early Breast Cancer
In the Korean phase II Neo-PATH trial reported in JAMA Oncology, Ahn et al found that neoadjuvant treatment with atezolizumab, pertuzumab/trastuzumab, and docetaxel produced a pathologic complete response in 61% of patients with HER2-positive stage II/III breast cancer treated with the regimen....
Risk of Oropharyngeal Cancer After a Positive HPV16-E6 Serology Test
In an analysis from the Human Papillomavirus Cancer Cohort Consortium (HPVC3) reported in the Journal of Clinical Oncology, Robbins et al found substantial risks of oropharyngeal cancer over time among persons, particularly males, with positive results on human papillomavirus (HPV) 16-E6 serologic...
Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
In a phase II study reported in The Lancet Oncology, L. Elizabeth Budde, MD, PhD, and colleagues found that mosunetuzumab—a CD20 × CD3 T-cell–engaging bispecific antibody that redirects T cells to eliminate malignant B cells—produced a high rate of complete response in patients with relapsed or...
Former NCI Director Takes Stock of His Accomplishments and Looks Ahead to the Next Challenge
After nearly 5 years as Director of the National Cancer Institute (NCI), interrupted by 7 months as Acting Commissioner for the U.S. Food and Drug Administration (FDA), Norman E. “Ned” Sharpless, MD, left his position on April 29 to concentrate on his family and contemplate his next career choice....
Moffitt Mourns the Loss of Research Giant Robert J. Gillies, PhD
Moffitt Cancer Center and the global research community have lost a great leader, scientist, and collaborator. Robert J. Gillies, PhD, died on June 7 after an extended illness. He was 69 years old. His recruitment in 2008 elevated Moffitt’s scientific stature, and his vision and work over the past...
Outcomes of the SARS–CoV-2 Omicron Variant Outbreak Among European Patients With Cancer
In an analysis from the retrospective OnCovid registry study reported in The Lancet Oncology, David J. Pinato, PhD, and colleagues detailed outcomes of the SARS–CoV-2 omicron variant outbreak among European patients with cancer. Study Details The analysis included 3,473 patients with cancer from...
Taxane Maintenance vs Surveillance in Advanced Ovarian Cancer
As reported in the Journal of Clinical Oncology by Copeland et al, the phase III Gynecologic Oncology Group 0212/NRG Oncology study has shown no improvement in overall survival with maintenance paclitaxel or paclitaxel poliglumex vs surveillance in patients with advanced ovarian, tubal, or...
Dual-Targeted Therapy Improves Outcomes vs Chemotherapy for Some Pediatric Patients With Low-Grade Glioma
The all-oral combination of dabrafenib plus trametinib—two targeted therapies—significantly improved the overall response rate vs standard-of-care chemotherapy with carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas. The clinical benefit rate...
Direct-Acting Antivirals in HCV-Associated Indolent Non-Hodgkin Lymphomas
As reported in the Journal of Clinical Oncology by Merli et al, the Fondazione Italiana Linfomi phase II BArT study has shown that primary treatment of hepatitis C virus (HCV)-associated indolent non-Hodgkin lymphomas with direct-acting antivirals resulted in sustained virologic response in all...
Addition of Trastuzumab/Pertuzumab to Perioperative FLOT Chemotherapy in HER2-Positive Esophagogastric Adenocarcinoma
In the German phase II PETRARCA trial of the AIO EGA Study Group, reported in the Journal of Clinical Oncology, Hofheinz et al found that the addition of trastuzumab and pertuzumab to perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) improved both the pathologic complete...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare and...
ASCO Statement on Supreme Court Decision in Dobbs v Jackson Women’s Health
On June 27, ASCO released a statement on the recent ruling in Dobbs v Jackson Women’s Health. ASCO is committed to the delivery of medically appropriate, equitable, evidence-based cancer care. For patients of child-bearing age, a cancer diagnosis raises medical considerations around pregnancy and...
FDA Approves Lisocabtagene Maraleucel for the Second-Line Treatment of Large B-Cell Lymphoma
On June 24, the U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with large B-cell lymphoma (LBCL) who have disease refractory to first-line chemoimmunotherapy or relapse within 12 months of...
Nivolumab in Combination With Chemotherapy and in Combination With Ipilimumab in Advanced Esophageal Squamous Cell Carcinoma
On May 27, 2022, nivolumab was approved for use in combination with fluoropyrimidine- and platinum-based chemotherapy and in combination with ipilimumab for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.1 Supporting Efficacy Data Approval was based on...
Nivolumab/Cabozantinib vs Sunitinib in First-Line Treatment for Advanced RCC: Overall Survival Analysis of CheckMate 9ER Trial
As reported in The Lancet Oncology by Robert J. Motzer, MD, and colleagues, the protocol-defined final overall survival analysis of the phase III CheckMate 9ER trial showed a significant benefit with nivolumab/cabozantinib vs sunitinib in previously untreated patients with advanced renal cell...
Cabozantinib and Atezolizumab for Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Post–Hormonal Therapy
As reported in The Lancet Oncology by Neeraj Agarwal, MD, and colleagues, findings in the expansion cohort of the phase Ib COSMIC-021 trial indicate activity of the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer whose disease progressed ...
Rates of Active Surveillance Rising Among Men With Low-Risk Prostate Cancer but Still Suboptimal
Most men with low-risk prostate tumors now opt for active surveillance, but overtreatment remains a problem, according to data presented during the 2022 American Urological Association (AUA) Annual Meeting.1 A retrospective analysis of more than 20,000 patients with low-risk prostate cancer showed...
MRD-Guided Cessation of Treatment in Patients Receiving Venetoclax/Ibrutinib for Relapsed or Refractory CLL
In a phase II trial (HOVON141/VISION) reported in The Lancet Oncology, Arnon P. Kater, MD, PhD, and colleagues found a high rate of 12-month progression-free survival among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who stopped venetoclax/ibrutinib after achieving...
Addition of Atezolizumab to FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
In an Italian phase II trial (AtezoTRIBE) reported in The Lancet Oncology, Antoniotti et al found that the addition of atezolizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, irinotecan) and bevacizumab improved progression-free survival in the first-line treatment of patients with...
Intracranial Efficacy of Lorlatinib vs Crizotinib in ALK-Positive Advanced NSCLC
In a post hoc analysis from the phase III CROWN trial reported in the Journal of Clinical Oncology, Benjamin J. Solomon, MBBS, PhD, and colleagues found that progression-free survival and the risk of central nervous system (CNS) progression were improved with lorlatinib vs crizotinib in previously...
